Product architecture
What GenRx is, what is live, and where the boundaries sit.
- System and workflow map
- Module inventory and release state
- Programme OS and evidence-spine architecture
- Roadmap with explicit status labels
Controlled investor diligence
Inspect the evidence behind the investment case.
This surface defines the diligence package for qualified investor discussions. Sensitive company, financial, customer and security materials should be shared under appropriate access controls rather than exposed publicly.
This page is intentionally noindex. It does not imply that every listed document is already complete or public; it defines the diligence structure and access path.
Scientific validation
Evidence that the platform handles scientific claims and uncertainty responsibly.
- QA / QC reports and benchmark cases
- Evidence-class handling
- Model applicability and limitations
- Human-review and approval boundaries
Security & governance
Enterprise-readiness evidence for data, access and auditability.
- Authentication and access controls
- Data boundaries and infrastructure overview
- Audit / review controls
- Security roadmap and known gaps
Market model
A source-driven software opportunity rather than a generic-drug-market proxy.
- TAM / SAM / SOM formulas
- Customer-count and programme-volume sources
- Pricing / ACV assumptions
- Competitive-positioning evidence
Commercial evidence
Only verified customer and pipeline evidence belongs here.
- Customer discovery notes
- Pilot / design-partner funnel
- Contracts or LOIs where available
- Usage and retention evidence when available
Company & finance
Restricted materials used to evaluate the financing itself.
- Corporate structure and cap table
- Raise amount and use of funds
- Budget, runway and hiring plan
- Milestones and financing scenarios
Request investor diligence access
Access can be shared selectively after an investor discussion and any required confidentiality process.